BioCentury
ARTICLE | Company News

Seattle Genetics, Abbott, Astellas, Pfizer deal

February 20, 2012 8:00 AM UTC

Seattle Genetics disclosed in its 4Q11 earnings that it received undisclosed milestone payments from Abbott and Pfizer under separate 2011 deals granting the pharmas rights to use Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to undisclosed cancer targets. The payments were triggered by undisclosed preclinical events (see BioCentury Jan. 10, 2011 & March 28, 2011). ...